Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ganaplacide · KLU156, GNF-156

Small molecule · developed by Novartis Pharmaceuticals

Phase 2 Most advanced trial
NVS Developer

What is Ganaplacide?

Ganaplacide (KLU156, GNF-156, KAF156) is an oral antimalarial compound given as a sachet formulation together with lumefantrine (LUM-SDF) and combined with cipargamin (KAE609). It is being studied in uncomplicated Plasmodium falciparum malaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KLU156, GNF-156, KAF 156
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
85VMN9JU7A

Conditions studied

Uncomplicated Plasmodium Falciparum Malaria

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Ganaplacide

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.